# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 11-20 of 2566 results.
An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer
Status: Unknown status
Last Changed: Feb 26, 2018
First Received: Feb 26, 2018
Disease(s): Ovarian Cancer
Intervention(s): Trabectedin + PLD
Locations: Almaty oncological center, Almaty, Kazakhstan
Almaty regional oncological dispensary, Almaty, Kazakhstan
Kazakh institute of oncology and radiology, Almaty, Kazakhstan
Kazakh institute of oncology and radiology, Almaty, Kazakhstan
Astana Oncology Center, Astana, Kazakhstan
... and 6 other locations.
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Nov 06, 2019
First Received: Aug 21, 2018
Disease(s): Ovarian Cancer
Intervention(s): AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD), Placebo
Locations: Arizona Oncology, Phoenix, Arizona, United States
Kaiser Permanente Oakland, Oakland, California, United States
Stanford University, Palo Alto, California, United States
Kaiser Permanente Roseville, Roseville, California, United States
Kaiser Permanente Sacramento, Sacramento, California, United States
... and 19 other locations.
Oxford Ovarian Cancer Predict Chemotherapy Response 01
Status: Unknown status
Last Changed: Jan 17, 2013
First Received: Jan 17, 2013
Disease(s): Ovarian Cancer
Locations: Churchill Hospital, Oxford, United Kingdom
Engineered Immune Effectors Against Ovarian Cancer
Status: Recruiting
Last Changed: Sep 19, 2019
First Received: Dec 05, 2017
Disease(s): Ovarian Cancer
Intervention(s): OC-CTLs
Locations: Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China
SGI-110 in Combination With Carboplatin in Ovarian Cancer
Status: Completed
Last Changed: Jan 18, 2020
First Received: Sep 28, 2012
Disease(s): Ovarian Cancer
Intervention(s): SGI-110, Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel), Carboplatin
Locations: Norris Comprehensive Cancer Center- University of Southern California, Los Angeles, California, United States
University of Florida Shands Cancer Center, Gainesville, Florida, United States
Georgia Health Sciences University, Augusta, Georgia, United States
University of Chicago, Chicago, Illinois, United States
Melvin and Bren Simon Cancer Center- Indiana University, Indianapolis, Indiana, United States
... and 20 other locations.
The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer
Status: Completed
Last Changed: Aug 05, 2016
First Received: Aug 05, 2016
Disease(s): Ovarian Cancer
Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Status: Unknown status
Last Changed: Oct 11, 2016
First Received: May 17, 2012
Disease(s): Ovarian Cancer
Intervention(s): pazopanib in combination with weekly topotecan
Locations: Charité Campus Virchow-Klinikum, Berlin, Germany
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Status: Suspended
Last Changed: Jul 31, 2018
First Received: Jan 09, 2018
Disease(s): Ovarian Cancer
Intervention(s): OC-EIEs
Locations: Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, Yunnan, China
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
Status: Not yet recruiting
Last Changed: Jan 23, 2020
First Received: Jan 23, 2020
Disease(s): Ovarian Cancer
Intervention(s): Olaparib, Ceralasertib, Placebo to match olaparib
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
Status: Recruiting
Last Changed: Feb 20, 2020
First Received: May 03, 2019
Disease(s): Ovarian Cancer
Intervention(s): Palbociclib 125mg, Letrozole 2.5mg
Locations: Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
CPO Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil
Instituto Nacional do Câncer - INCA, Rio De Janeiro, Brazil
AC Camargo Cancer Center, São Paulo, Brazil
Hospital Beneficência Portuguesa, São Paulo, Brazil
... and 3 other locations.